Keywords
Eligibility Determination ×
Carcinoma, Hepatocellular ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

89 Search results.

Eligibility Hepatocellular Carcinoma NCT02504983

- 4/14/19 - 1 form, 2 itemgroups, 28 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02504983

Eligibility Hepatocellular Carcinoma NCT02460991

- 4/13/19 - 1 form, 2 itemgroups, 25 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02460991

Eligibility Hepatocellular Carcinoma NCT02460835

- 4/13/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02460835

Eligibility Hepatocellular Carcinoma NCT02436044

- 4/13/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC; ODM derived from: https://clinicaltrials.gov/show/NCT02436044

Eligibility Hepatocellular Carcinoma NCT02435953

- 4/13/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02435953

Eligibility Hepatocellular Carcinoma NCT02290977

- 4/13/19 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Transarterial Chemoembolization (TACE) With Radiation Therapy (RT) in Advanced Hepatocellular Carcinoma (HCC); ODM derived from: https://clinicaltrials.gov/show/NCT02290977

Eligibility Hepatocellular Carcinoma NCT02253511

- 4/13/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02253511

Eligibility Hepatocellular Carcinoma NCT02074202

- 4/12/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02074202

Eligibility Hepatocellular Carcinoma NCT02046356

- 4/12/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Early Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency Ablation; ODM derived from: https://clinicaltrials.gov/show/NCT02046356

Eligibility Hepatocellular Carcinoma (HCC) NCT02508467

- 4/12/19 - 1 form, 1 itemgroup, 15 items, 1 language
Itemgroup: Criteria
A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02508467

Eligibility Carcinoma, Hepatocellular NCT02421185

- 2/18/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Participants With Advanced Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02421185

Eligibility Carcinoma, Hepatocellular NCT02293850

- 2/18/19 - 1 form, 2 itemgroups, 34 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02293850